CIK细胞与白介素-2回输联合同步化疗治疗晚期非小细胞肺癌临床研究  

Clinical study of cytokine-induced killer cells and IL-2 combined with synchronous chemotherapy for advanced non-small-cell lung cancer

作　　者：尹先哲[1] 王苗[1] 杜锋[1] 刘丽娜[1] 蔡芳[1] 李毅星[1] 丁旭萌[1] 

机构地区：[1]河南省南阳市第二人民医院,河南南阳473012

出　　处：《山东医药》2012年第28期21-22,25,共3页Shandong Medical Journal

摘　　要：目的观察评价细胞因子诱导杀伤(CIK)细胞与白介素-2回输联合紫杉醇和顺铂方案(TP方案)化疗治疗晚期非小细胞肺癌的近远期疗效。方法将105例患者随机分为两组,治疗组52例采用过继性CIK细胞与白介素-2回输联合顺铂化疗;对照组53例行单纯TP化疗。观察指标:疗效、生存质量、毒性、无进展生存期、总生存率。结果治疗组总有效率明显高于对照组,生活质量显著提高,毒副作用未增加,无进展生存期和总生存期明显延长。结论 CIK细胞与白介素-2回输联合紫杉醇和顺铂治疗晚期非小细胞肺癌能够改善生活质量,延长生存期。Objective To observe the clinical efficacy of chemotherapy using paclitaxel and cisplatin combined with IL-2 and cytokine-induced kiUer （CIK） cells to advanced non-small cell lung cancer （NSCLC）. Methods 105 patients of NSCLC were randomly divided into 52 patients of treatment group （ IL-2 and CIK cells biotherapy plus chemotherapy） and 53 patients of control group （ chemotherapy alone）. The recent and long term efficacy, quality of life （ QOL）, progress free survival （PFS） ,overall survival （OS） and toxic effect were compared between the two groups. Results The QOL was improved in patients of treatment group campared with control group, disease control rate （DCR） was higher, the PFS and OS were significantly prolonged. The RR and toxic effect had no significant difference between the two groups. Conclusions It is safe to patients by autologous CIK ceils transfusion. Chemotherapy combined with IL-2 and CIK ceils have benefits for the patients suffering from advanced NSCLC, and there is advantage to chemotherapy alone in terms of QOL, PFS, DCR and OS.

关 键 词：癌 非小细胞肺 CIK细胞 过继免疫治疗 化疗 

分 类 号：R730.51[医药卫生—肿瘤]